Jardiance Will Come Back as No. 1 in Japan SGLT2 Space after CKD Launch: NBI Chair

Nippon Boehringer Ingelheim Chairman & President Yoshiaki Aono Nippon Boehringer Ingelheim’s Jardiance (empagliflozin) fell to the second spot in the Japanese SGLT2 market in 2021, but its planned label expansion into chronic kidney disease (CKD) will help it retrieve the...read more